Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers.
Brandon M Huffman, Vasily N Aushev, Griffin L Budde, Joseph Chao, Farshid Dayyani, Diana Hanna, Gregory P Botta, Daniel V T Catenacci, Steven B Maron, Shifra Krinshpun, Shruti Sharma, Giby V George, Meenakshi Malhotra, Adham Jurdi, Solomon Moshkevich
December 2022 JCO Precis OncolSynopsis of Social media discussions
Discussions highlight the publication's significance, with phrases like 'highly prognostic' and 'exceptional response' indicating enthusiasm about potential advancements in patient management. Contributors emphasize the feasibility of ctDNA detection in post-surgical settings, noting that it can enhance risk stratification during curative therapy, which suggests a proactive approach to cancer treatment using modern technology.
Agreement
Moderate agreementMost discussions reflect a positive reception to the findings, indicating a shared understanding of their significance.
Interest
High level of interestMany posts express strong curiosity about the implications of ctDNA analysis, showing relevance to ongoing research and patient care.
Engagement
Moderate level of engagementSome contributors delve into specific patient cases, demonstrating a deeper analysis of the publication's methodology and results.
Impact
High level of impactThere is a strong consensus that the publication has substantial potential to influence treatment approaches in esophageal and gastric cancers.
Social Mentions
YouTube
1 Videos
106 Posts
News
52 Articles
Metrics
Video Views
23
Total Likes
285
Extended Reach
540,765
Social Features
159
Timeline: Posts about article
Top Social Media Posts
Sam Klempner
Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers https://t.co/aQ5q02t2zl
view full post
Pashtoon Kasi MD, MS
view full post
Brandon Huffman, MD
Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancers. See our @JCOPO_ASCO manuscript out today: https://t.co/63RnOisFeZ #ctDNA
view full post
Pashtoon Kasi MD, MS
Sounds like we were popular @JCOPO_ASCO @ASCO
view full post
Arndt Vogel
view full post
Posts referencing the article
ctDNA Assessment for Recurrence Risk in Esophagogastric Cancers
This video presents insights from Dr. Brandon Huffman on the analysis of circulating tumor DNA (ctDNA) for predicting recurrence risks in esophageal and gastric cancers. Learn about the correlation between ctDNA detection and shorter recurrence-free survival, providing valuable implications for patient management.
April 3, 2024
23 views
-
RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postFebruary 2, 2023
18
-
Rahul Pathak
@SumitPathak261 (Twitter)RT @JCOPO_ASCO:
view full postDecember 22, 2022
10
-
OGCancerNI
@OGCancerNI (Twitter)RT @JCOPO_ASCO:
view full postDecember 19, 2022
10
-
ASCO
@ASCO (Twitter)RT @JCOPO_ASCO:
view full postDecember 19, 2022
10
-
raerae
@raely_31 (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 18, 2022
17
-
Zach Yeung MD
@zpyeung (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 18, 2022
17
-
Adzabe Nana-Yao MD
@adzabe_ny (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 18, 2022
17
-
Dr Shantanu SG Kulkarni
@CancerYoddha (Twitter)RT @JCOPO_ASCO:
view full postDecember 17, 2022
10
-
Eric Thompson, Ph.D.
@AZBioMarkers (Twitter)RT @pashtoonkasi: Building on our @JCOPO_ASCO publication, I have this patient with stage-IV HER2➕➕➕gastric cancer with an exceptional resp…
view full postDecember 17, 2022
2
-
Sewanti Limaye
@SewantiLimaye (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 17, 2022
17
-
Arto Kokkola
@ArtoKokkola (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 17, 2022
17
-
Santhosh Ambika
@RenoHemonc (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 17, 2022
17
-
OncoAlert
@OncoAlert (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 17, 2022
17
-
Pashtoon Kasi MD, MS
@pashtoonkasi (Twitter)Building on our @JCOPO_ASCO publication, I have this patient with stage-IV HER2➕➕➕gastric cancer with an exceptional response who made it to surgery. However, never turned #ctDNA➖. High risk path. Gave T-DXd “2nd” line➡️➖right away & on a holiday.
view full postDecember 17, 2022
17
2
-
Tevfik Ergül
@tergul06 (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 17, 2022
17
-
Ricardo Carvalho
@rcarvalhoonco (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 17, 2022
17
-
Katsuaki Maehara
@KatsuakiMaehara (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 17, 2022
17
-
Masoom Kasi
@masoomkassi (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 17, 2022
17
-
Marco A
@aurelioassad (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 17, 2022
17
-
Michael R Freund MD
@mikifreund (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 17, 2022
17
-
Arun Nagarajan
@ArunNagarajanMD (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 17, 2022
17
-
Umberto Malapelle
@UmbertoMalapel1 (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 17, 2022
17
-
Gavin Strachan
@CCGav (Twitter)RT @pashtoonkasi: Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 17, 2022
17
-
Pashtoon Kasi MD, MS
@pashtoonkasi (Twitter)Sounds like we were popular @JCOPO_ASCO @ASCO
view full postDecember 17, 2022
42
17
-
Pashtoon Kasi MD, MS
@pashtoonkasi (Twitter)RT @JCOPO_ASCO:
view full postDecember 16, 2022
10
-
Daniel Catenacci
@DocCatenacci (Twitter)RT @JCOPO_ASCO:
view full postDecember 16, 2022
10
-
Adham Jurdi
@OncoJurdi (Twitter)RT @JCOPO_ASCO:
view full postDecember 16, 2022
10
-
Sam Klempner
@KlempnerSam (Twitter)RT @JCOPO_ASCO:
view full postDecember 16, 2022
10
-
Brandon Huffman, MD
@BHuffmanMD (Twitter)RT @JCOPO_ASCO:
view full postDecember 16, 2022
10
-
JCO Precision Oncology
@JCOPO_ASCO (Twitter)December 16, 2022
21
10
-
Mónica Meneses
@MoniquMeneses (Twitter)RT @ArndtVogel:
view full postDecember 15, 2022
13
-
Ali Erdem
@life_walker (Twitter)RT @ArndtVogel:
view full postDecember 15, 2022
13
-
Nelly, Chien-Jui Huang
@nellyhuang91 (Twitter)RT @ArndtVogel:
view full postDecember 15, 2022
13
-
DARIO SERAFINO
@DarioWSeraf (Twitter)RT @ArndtVogel:
view full postDecember 15, 2022
13
-
Suneel Kamath MD
@SKamath_MD (Twitter)RT @ArndtVogel:
view full postDecember 15, 2022
13
-
Sukeshi Arora MD
@DrSukeshiArora (Twitter)RT @ArndtVogel:
view full postDecember 15, 2022
13
-
Dr Zachary Veitch
@z_veitch (Twitter)RT @ArndtVogel:
view full postDecember 15, 2022
13
-
ilyas sahin, MD
@ilyassahinMD (Twitter)December 15, 2022
26
-
Gregory Botta
@gregorybotta (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 15, 2022
18
-
Emma B. Holliday MD
@DrEmmaHolliday (Twitter)RT @ArndtVogel:
view full postDecember 15, 2022
13
-
Garrett Green, MD
@ggreen1986 (Twitter)RT @ArndtVogel:
view full postDecember 15, 2022
13
-
OncoAlert
@OncoAlert (Twitter)RT @ArndtVogel:
view full postDecember 15, 2022
13
-
Asaf Maoz
@asaf_maoz (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 14, 2022
18
-
JCO Precision Oncology
@JCOPO_ASCO (Twitter)RT @ArndtVogel:
view full postDecember 14, 2022
13
-
Wolfgang Kunz
@WolfgangGKunzMD (Twitter)RT @ArndtVogel:
view full postDecember 14, 2022
13
-
Alan Burguete-Torres M.D.
@dralanburguete (Twitter)RT @ArndtVogel:
view full postDecember 14, 2022
13
-
Arndt Vogel
@ArndtVogel (Twitter)December 14, 2022
36
13
-
@investigando
@rocatanho (Twitter)Detección de DNA tumoral circulante en el postoperatorio del cáncer esofagogástrico es factible y permite mejorar la estratificación y pronóstico del riesgo del paciente durante la terapia con intención curativa #ctDNA #risk #cancer https://t.co/Q0sIio1z8g
view full postDecember 14, 2022
-
Jonathan Loree
@jonathanloree (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 14, 2022
15
-
Brandon Huffman, MD
@BHuffmanMD (Twitter)RT @pashtoonkasi:
view full postDecember 14, 2022
18
-
Pashtoon Kasi MD, MS
@pashtoonkasi (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 14, 2022
15
-
Pashtoon Kasi MD, MS
@pashtoonkasi (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 14, 2022
18
-
cfDNA papers
@cfDNA_papers (Twitter)Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers https://t.co/EEJZER0Hq5 https://t.co/XYXs93GQSC
view full postDecember 12, 2022
1
-
Ryan Palusak
@Palusak (Twitter)RT @pashtoonkasi:
view full postDecember 12, 2022
18
-
TerriConneran
@TerriConneran (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 11, 2022
18
-
Alexandra Gangi, MD
@AGangiMD (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 11, 2022
18
-
R8Plus
@AAABiotech (Twitter)RT @pashtoonkasi:
view full postDecember 11, 2022
18
-
BE.Johnson.MD
@bejmedonc (Twitter)RT @pashtoonkasi:
view full postDecember 11, 2022
18
-
Ahmed Tayel
@AhmedTayel13 (Twitter)RT @pashtoonkasi:
view full postDecember 11, 2022
18
-
Brandon Huffman, MD
@BHuffmanMD (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 11, 2022
18
-
Dr Zachary Veitch
@z_veitch (Twitter)RT @pashtoonkasi:
view full postDecember 11, 2022
18
-
Pashtoon Kasi MD, MS
@pashtoonkasi (Twitter)RT @pashtoonkasi:
view full postDecember 11, 2022
18
-
Gregory Botta
@gregorybotta (Twitter)RT @pashtoonkasi:
view full postDecember 9, 2022
18
-
Gregory Botta
@gregorybotta (Twitter)https://t.co/VXVA6YhTqc
view full postDecember 9, 2022
-
Suneel Kamath MD
@SKamath_MD (Twitter)RT @pashtoonkasi:
view full postDecember 9, 2022
18
-
JCO Precision Oncology
@JCOPO_ASCO (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 9, 2022
18
-
Griffin Budde, PharmD
@GBudde_SkinMRD (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 9, 2022
18
-
Griffin Budde, PharmD
@GBudde_SkinMRD (Twitter)RT @pashtoonkasi:
view full postDecember 9, 2022
18
-
Griffin Budde, PharmD
@GBudde_SkinMRD (Twitter)RT @OncoJurdi: Hot off the press! @JCOPO_ASCO In a multicenter RWE collaboration, Signatera #ctDNA assay is highly prognostic in Esophagea…
view full postDecember 9, 2022
3
-
Griffin Budde, PharmD
@GBudde_SkinMRD (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 9, 2022
15
-
Guglielmo Vetere, MD
@Guv_onc (Twitter)RT @pashtoonkasi:
view full postDecember 9, 2022
18
-
爱母Q
@Q34566201 (Twitter)RT @pashtoonkasi:
view full postDecember 9, 2022
18
-
Rafeh Naqash, MD, FASCO
@thenasheffect (Twitter)RT @OncoJurdi: Hot off the press! @JCOPO_ASCO In a multicenter RWE collaboration, Signatera #ctDNA assay is highly prognostic in Esophagea…
view full postDecember 9, 2022
3
-
Efrat Dotan MD
@efratdotan (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 9, 2022
15
-
Asaf Maoz
@asaf_maoz (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 9, 2022
15
-
Christopher G. Smith
@Chris_G_Smith1 (Twitter)RT @pashtoonkasi:
view full postDecember 9, 2022
18
-
Ricardo Carvalho
@rcarvalhoonco (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 9, 2022
15
-
Pamela Almeida
@pam65230529 (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 9, 2022
18
-
Patxi Queipo
@patxiqueipo (Twitter)RT @pashtoonkasi:
view full postDecember 9, 2022
18
-
Jp Solar Vasconcelos
@jaypsv (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 9, 2022
18
-
Ali Erdem
@life_walker (Twitter)RT @pashtoonkasi:
view full postDecember 9, 2022
18
-
Ali Erdem
@life_walker (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 9, 2022
18
-
Jun Gong
@jgong15 (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 9, 2022
15
-
Masoom Kasi
@masoomkassi (Twitter)RT @pashtoonkasi:
view full postDecember 9, 2022
18
-
filippo masini
@filimasini (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 9, 2022
15
-
Elad Sharon
@EladSharonMD (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 9, 2022
15
-
Davide Ciardiello
@DCiardiello (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 9, 2022
15
-
Benjamin Weinberg, MD, FACP
@benweinbergmd (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 8, 2022
15
-
Alan Burguete-Torres M.D.
@dralanburguete (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 8, 2022
18
-
Elad Sharon
@EladSharonMD (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 8, 2022
18
-
Ricardo Silva
@silvamricardo (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 8, 2022
18
-
Ricardo Silva
@silvamricardo (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 8, 2022
15
-
ctSEQpapers
@ctSEQ_papers (Twitter)PubMed_ Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers https://t.co/h2zQOGzZj9
view full postDecember 8, 2022
-
Anwaar Saeed
@AnwaarSaeed3 (Twitter)RT @pashtoonkasi:
view full postDecember 8, 2022
18
-
Adham Jurdi
@OncoJurdi (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 8, 2022
18
-
Alejandro Rosales
@HpbNicaragua (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 8, 2022
18
-
JCO Precision Oncology
@JCOPO_ASCO (Twitter)RT @OncoJurdi: Hot off the press! @JCOPO_ASCO In a multicenter RWE collaboration, Signatera #ctDNA assay is highly prognostic in Esophagea…
view full postDecember 8, 2022
3
-
JCO Precision Oncology
@JCOPO_ASCO (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 8, 2022
15
-
JCO Precision Oncology
@JCOPO_ASCO (Twitter)RT @pashtoonkasi:
view full postDecember 8, 2022
18
-
Pashtoon Kasi MD, MS
@pashtoonkasi (Twitter)December 8, 2022
44
18
-
Adham Jurdi
@OncoJurdi (Twitter)Hot off the press! @JCOPO_ASCO In a multicenter RWE collaboration, Signatera #ctDNA assay is highly prognostic in Esophageal and Gastric cancers. HR=10.7 in postsurgical window and 17.7 during surveillance. https://t.co/9WPwv0Hu3C https://t.co/acdR5nP5Gp
view full postDecember 8, 2022
7
3
-
Brandon Huffman, MD
@BHuffmanMD (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 8, 2022
15
-
Geoff Oxnard MD
@geoff_oxnard (Twitter)RT @KlempnerSam: Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk…
view full postDecember 8, 2022
15
-
Michael LaPelusa, MD
@MichaelLaPelusa (Twitter)RT @BHuffmanMD: Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancer…
view full postDecember 8, 2022
18
-
Brandon Huffman, MD
@BHuffmanMD (Twitter)Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancers. See our @JCOPO_ASCO manuscript out today: https://t.co/63RnOisFeZ #ctDNA
view full postDecember 8, 2022
43
18
-
Sam Klempner
@KlempnerSam (Twitter)Fellow led project from @BHuffmanMD who is now faculty @DanaFarber @ASCO @JCOPO_ASCO Analysis of ctDNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers https://t.co/aQ5q02t2zl
view full postDecember 8, 2022
47
15
Abstract Synopsis
- Circulating tumor DNA (ctDNA) analyses show promise for risk assessment in esophagogastric cancers (EGC), similar to its established use in colon and breast cancers.
- A study analyzed ctDNA levels in 295 EGC patients pre- and post-surgery, finding high detection rates that correlated with disease recurrence.
- Results indicated that ctDNA detection at various points post-surgery significantly predicted shorter recurrence-free survival, highlighting its potential role in patient management after curative treatment.
Lauren
@elrenres (Twitter)